Background/Aim: The pharmaco-invasive (PI) therapy is recommended strategy in patients (pts) with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (pPCI). The primary endpoint was to find the cohorts of pts who are not treated by any reperfusion therapy (RT) and the second endpoint was to see the outcome of the pts treated with RT, in a transition country without fully applicable PI therapy.
Methods:The data used are those of the Hospital National Registry for Acute Coronary Syndrome of Serbia (HORACS).
Results:The significant predictors of the withdrawing of the application of any RT in the model (c 75.6%, SE 0.004, 95% CI 0.748-0.761) were age (≥65 yr), heart failure (Killip II-IV), diabetes, and the time to first medical contact (FMC) (>360 min). In patients without RT, mortality was 15.7%, in pts treated with fibrinolysis (FT) was 10.5% and in pts treated with pPCI was 6.2% (p<0.000). Within 3 hours to FMC, higher in-hospital mortality was in FT pts (FT 8.7% vs. pPCI 4.3%). FT treated patients were older, had more comorbidities and heart failure (HF). However, after propensity score matching, in order to adjust the differences among the pts, the mortality rate remained higher, but not statistically significant (FT 8.8%. vs. pPCI 6.4%).
Conclusions:The balance of the best cost-benefit strategies for better use of RT is difficult to achieve in transition countries. The possibility for timely pPCI and PI therapy is not applicable, in high risk patients, older, pts with HF and diabetes, especially.
Key words: acute myocardial infarction with ST elevation, reperfusion therapy, transition countries, high-risk patientsZaključak: Primena reperfuzione terapije, uz postignuti idealan balans potrošnje i koristi je teško izvodljiva u zemljama u tranziciji. Mogućnosti za blagovremenu primenu pPCI, kao i FI terapije, posebno su ograničene kod visoko rizičnih, starijih bolesnika, kod bolesnika sa znacima SI, komorbiditetima i dijabetesom.Ključne reči: akutni infarkt miokarda sa ST elevacijom, reperfuziona terapija, zemlje u tranziciji, visoko rizični bolesnici